Theravance Biopharma Files 8-K on Financial Condition

Ticker: TBPH · Form: 8-K · Filed: Feb 26, 2024 · CIK: 1583107

Theravance Biopharma, Inc. 8-K Filing Summary
FieldDetail
CompanyTheravance Biopharma, Inc. (TBPH)
Form Type8-K
Filed DateFeb 26, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, 8-K

TL;DR

**Theravance Biopharma just dropped an 8-K on their financial results, standard stuff for investors to check out.**

AI Summary

Theravance Biopharma, Inc. filed an 8-K on February 26, 2024, to report on its results of operations and financial condition. The filing indicates the company's business address as Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands, with a business phone number of 650-808-6000. This report is a standard disclosure under Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing provides an update on Theravance Biopharma's financial health and operational performance, which is crucial for investors to assess the company's stability and future prospects.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any specific new risks or events.

Key Players & Entities

  • Theravance Biopharma, Inc. (company) — Registrant
  • February 26, 2024 (date) — Date of earliest event reported and filing date
  • Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands (company) — Business address
  • 650-808-6000 (dollar_amount) — Business phone number
  • 001-36033 (company) — Commission File Number

FAQ

What is the purpose of this 8-K filing by Theravance Biopharma, Inc.?

The 8-K filing by Theravance Biopharma, Inc. is to report on its results of operations and financial condition, as well as financial statements and exhibits, as per Item Information.

When was the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing was February 26, 2024.

What is the business address of Theravance Biopharma, Inc. as stated in the filing?

The business address of Theravance Biopharma, Inc. is PO Box 309 Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands, KY1-1104.

Under which section of the Securities Exchange Act of 1934 was this report filed?

This report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is the Commission File Number for Theravance Biopharma, Inc.?

The Commission File Number for Theravance Biopharma, Inc. is 001-36033.

Filing Stats: 574 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-02-26 16:16:00

Key Financial Figures

  • $0.00001 — e on which registered Ordinary Share $0.00001 Par Value TBPH NASDAQ Global Marke

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On February 26, 2024, Theravance Biopharma, Inc. (the "Company") issued a press release and is holding a conference call regarding its financial results for the quarter and full year ended December 31, 2023 and a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and a copy of materials that will accompany the call is furnished as Exhibit 99.2 to this Current Report. The information in Item 2.02 and in Item 9.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act of 1934"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release dated February 26, 2024 99.2 Slide deck entitled Fourth Quarter & Full Year 2023 Financial Results and Business Update 104 Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THERAVANCE BIOPHARMA, INC. Date: February 26, 2024 By: /s/ Aziz Sawaf Aziz Sawaf Senior Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.